Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
Journal
Lung Cancer
Journal Volume
60
Journal Issue
2
Pages
215-221
Date Issued
2008
Abstract
Background: Gemcitabine and paclitaxel are both indicated for advanced nonsmall cell lung cancer (NSCLC) patients. Combinations of gemcitabine and paclitaxel with various doses and schedules were shown to be effective treatment for these patients. Nevertheless, the survival outcome of these patients is not clear. Patients and methods: Patients with advanced NSCLC in a phase II study of weekly paclitaxel and gemcitabine as first-line treatment were followed until their death. Second- and further-lines of treatment were recorded. Results: Thirty-seven patients receiving a total of 188 cycles of gemcitabine and paclitaxel treatment were accrued. Toxicities were mild. Twenty-three patients had partial response to treatment (overall response rate, 62%; 95% confidence interval (CI), 46-78%). Median time to treatment failure was 6.0 months. Twenty-seven (73%) patients received second-line anticancer drug treatment. Twenty-three (62%) patients were able to receive platinum doublet as second-line chemotherapy. Median survival after second-line treatment was 10.9 months. Median, 1- and 2-year survivals of 37 patients were 16.8 months, 59% and 27%, respectively. There was a statistically significant difference in median survival between patients who could or could not receive second-line treatment (21.9 vs. 3.1 months, p < 0.00001). Conclusions: Weekly paclitaxel with gemcitabine is effective and well tolerated as first-line treatment for advanced NSCLC patients. The favorable survival may be due to platinum doublet second-line chemotherapy. ? 2007 Elsevier Ireland Ltd. All rights reserved.
SDGs
Other Subjects
carboplatin; cisplatin; docetaxel; etoposide; gefitinib; gemcitabine; navelbine; paclitaxel; platinum; adult; advanced cancer; aged; alopecia; anemia; article; bone marrow toxicity; cancer chemotherapy; cancer diagnosis; cancer patient; cancer radiotherapy; cancer staging; cancer survival; clinical article; clinical trial; confidence interval; constipation; controlled study; diarrhea; drug fatality; febrile neutropenia; female; human; human tissue; infection; leukopenia; liver toxicity; lung non small cell cancer; male; monotherapy; multiple cycle treatment; nausea and vomiting; nephrotoxicity; neurotoxicity; phase 2 clinical trial; priority journal; statistical significance; survival rate; survival time; thrombocytopenia; treatment failure; treatment outcome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel
Type
journal article